



Early View

Original article

Burden and Risk Factors for *Pseudomonas aeruginosa* Community-acquired Pneumonia: a Multinational Point Prevalence Study of Hospitalised Patients

Marcos I. Restrepo, Bettina L. Babu, Luis F. Reyes, James D. Chalmers, Nilam J. Soni, Oriol Sibila, Paola Faverio, Catia Cilloniz, William Rodriguez-Cintron, Stefano Aliberti

Please cite this article as: Restrepo MI, Babu BL, Reyes LF, *et al.* Burden and Risk Factors for *Pseudomonas aeruginosa* Community-acquired Pneumonia: a Multinational Point Prevalence Study of Hospitalised Patients. *Eur Respir J* 2018; in press (<https://doi.org/10.1183/13993003.01190-2017>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2018

TITLE: Burden and Risk Factors for *Pseudomonas aeruginosa* Community-acquired Pneumonia: a Multinational Point Prevalence Study of Hospitalised Patients

AUTHORS: Marcos I. Restrepo^{1,2}, Bettina L. Babu^{1,2}, Luis F. Reyes³, James D. Chalmers⁴, Nilam J. Soni^{1,2}, Oriol Sibila⁵, Paola Faverio⁶, Catia Cilloniz⁷, William Rodriguez-Cintron⁸ and Stefano Aliberti⁹.

AFFILIATIONS: ¹Division of Pulmonary Diseases & Critical Care Medicine, University of Texas Health - San Antonio, San Antonio, TX; ²Division of Pulmonary Diseases & Critical Care Medicine, South Texas Veterans Health Care System, San Antonio, TX, USA; ⁴ Department of microbiology, Universidad de la Sabana, Bogota, Colombia; ⁴School of Medicine, University of Dundee, Dundee, UK; ⁵Servei de Pneumologia, Departament de Medicina, Hospital Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; ⁶Cardio-Thoracic-Vascular Department, University of Milan Bicocca, Respiratory Unit, San Gerardo Hospital, ASST di Monza, Monza, Italy; ⁷Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona – Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), CIBER, Spain; ⁸Pulmonary/Critical Care Medicine VA Caribbean Healthcare System, USA; and ⁹Department of Pathophysiology and Transplantation, University of Milan, Cardio-thoracic unit and Adult Cystic Fibrosis Centre, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.

CORRESPONDING AUTHOR: Marcos I. Restrepo, MD, MSc, PhD; South Texas Veterans Health Care System ALMD - 7400 Merton Minter Boulevard - San Antonio Texas, 78229; Phone: (210)-617-5256 Email: restrepom@uthscsa.edu

Take Home Message: *P. aeruginosa* is infrequent in CAP patients. Specific risk factors should be assessed when choosing antibiotics for CAP

KEYWORDS: Community-Acquired Pneumonia, *Pseudomonas aeruginosa*, risk factors, prevalence

ABSTRACT

Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic antibiotic resistance to the most frequently used antibiotics in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with *P. aeruginosa*-CAP are limited. We assessed the multinational burden and specific risk factors associated with *P. aeruginosa*-CAP.

We enrolled 3,193 patients in 54 countries with confirmed diagnosis of CAP that underwent microbiological testing at admission. Prevalence was calculated according to the identification of *P. aeruginosa*. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant *P. aeruginosa*-CAP.

The prevalence of *P. aeruginosa* and antibiotic-resistant *P. aeruginosa*-CAP was 4.2% and 2.0%, respectively. The rate of *P. aeruginosa* CAP in patients with prior infection/colonization due to *P. aeruginosa* and at least one of the three independently associated chronic lung diseases [*i.e.*, tracheostomy, bronchiectasis and/or very severe COPD]) was 67%. In contrast, the rate of *P. aeruginosa* CAP was 2% in patients without prior *P. aeruginosa* infection/colonization and none of the selected chronic lung diseases.

The multinational prevalence of *P. aeruginosa*-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.

INTRODUCTION

Community acquired pneumonia (CAP) is a leading infectious cause of morbidity and mortality worldwide[1, 2]. Five to six billion people are diagnosed with CAP and more than 3.5 million people die annually secondary to CAP[1, 3]. Several viruses and bacteria cause CAP[4], but *Streptococcus pneumoniae* remains the most frequently identified bacterial pathogen in adults[5]. During the last few decades, the aetiology of CAP has been changing; antibiotic-resistant bacteria that were thought to be important only in hospital settings are now becoming more prevalent in community settings[6-8]. The evolution of this new pathogen ecology is threatening our capacity to treat patients with CAP[9-11].

Pseudomonas aeruginosa, a Gram-negative bacterium, intrinsically resistant to several groups of antibiotics, such as β -lactams[12], has been frequently reported in CAP patients with specific health care associated risk factors, such as residence in a nursing home and hospitalization during the past 90 days (*i.e.*, health care associated pneumonia, HCAP)[13-15]. Moreover, severe illnesses and poor clinical outcomes have been linked to *P. aeruginosa* infection in patients with CAP[15-17]. During recent years, *P. aeruginosa* circulating strains tend to have higher resistance patterns to anti-pseudomonal antibiotics, leading to infections that are challenging to treat[6].

The prevalence of CAP due to *P. aeruginosa* varies significantly between different patient groups and specific risk factors for *P. aeruginosa*-CAP are controversial[18, 19]. Currently available data about the prevalence of *P. aeruginosa*-CAP and its resistance patterns are limited to single centre studies[15, 20] and studies with several methodological limitations[15, 21-23]. In a meta-analysis, *Chalmers et al.* reported data from 22 studies a prevalence ranging from 0 to 23% in different CAP populations and a pool prevalence of 8.6% for *P. aeruginosa* in patients with multidrug resistant risk factors and 4% in patients without risk factors[24]. All were single centre/region and majority were rated as poor methodological status[24]. As a result, the true prevalence of *P. aeruginosa*-CAP globally is unknown. Currently, the risk factors associated with *P. aeruginosa* infection recognised by Infectious Diseases Society of America/ American Thoracic Society

(IDSA/ATS) guidelines for HCAP differ from those published in the CAP guidelines [13, 25]. Further, the global prevalence of multi-drug resistant (MDR) *P. aeruginosa* in CAP patients is unknown. Therefore, to close the gap regarding the global prevalence and the risk factors associated with *P. aeruginosa*, we designed a multinational, multicentre, worldwide study to determine the point prevalence of *P. aeruginosa*, its antibiotic resistance patterns, and the associated risk factors in hospitalised patients with CAP.

MATERIALS AND METHODS

Study Design

This is a multicentre, point-prevalence study of hospitalised patients with CAP in 222 hospitals in 54 countries. The coordinating institution for this project was the University of Texas Health San Antonio (UT Health) in San Antonio, Texas, USA. The UT Health Institutional Review Board approved the project to collect data and serve as a coordinating institution for the study (IRB# HSC20150184E). Study sites had to comply with local and national research regulations to participate in the study. Electronic invitations to participate were sent to members of various medical professional societies representing physicians specializing in infectious diseases, pulmonary, critical care, and internal medicine. Additionally, first authors of previously published studies of MDR pathogens in CAP were sent individual invitations. This project received no funding. Subjects were enrolled on four randomly selected days in March, April, May, and June of 2015. Each site investigator selected the study days to participate in compliance with the IRB stipulations, and avoid potential patient de-identification[26]. Due to the observational nature of the study, patient consent was not required.

Study Subjects

Inclusion criteria

Patients ≥ 18 years of age hospitalised with CAP were eligible for the study. CAP had to be diagnosed per the current IDSA/ATS guidelines[13]: presence of new pulmonary infiltrates on thoracic imaging (chest radiograph, computed chest tomography, or lung ultrasound) during the initial 48 hours of hospitalization and ≥ 1 of the following conditions: 1) novel or increased cough with or without sputum production and/or purulent

respiratory secretions; 2) fever (oral or rectal temperature ≥ 37.8 ° C) or hypothermia (oral or rectal temperature < 36 ° C); 3) signs of systemic inflammation (abnormal white blood cell count [leucocytosis $> 10,000/\text{cm}^3$, bandemia $> 10\%$, leukopenia $< 4,000/\text{cm}^3$], procalcitonin levels above the local upper limit of normal, or increased C-reactive protein)[26].

Exclusion criteria

Patients were excluded from participating in the study if they had hospital-acquired pneumonia (HAP) or ventilator associated pneumonia (VAP)[25]. Patients without microbiological testing from either blood, lower respiratory tract cultures, or sputum collected within 24 hours of hospital admission were also excluded.

Data collection

Data was collected and managed using REDCap™ (Research Electronic Data Capture), an electronic data capture tool hosted on the UT Health San Antonio's server. REDCap™ is a protected web-based application designed to collect research data[27]. Confirmation of microbiological results and all electronic data entry had to be completed within 7 days of study enrolment.

Microbiological analysis

Diagnostic testing, such as blood cultures and respiratory collection; and clinical care decisions were decided by attending physicians, not per study protocol[26]. Local microbiological testing protocols were used to process blood and sputum samples collected within the first 24 hours of hospitalization. If available, data on pleural fluid, tracheobronchial aspirate, and bronchoalveolar lavage fluid were collected. Local testing executed by each hospital included respiratory and blood cultures, urinary antigen and drug susceptibility testing. Local quality control protocols for Minimum Inhibitory Concentration (MIC) breakpoints and Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards were followed according with local regulations and protocols[28, 29].

Study definitions

Patients that required invasive respiratory and/or vasopressor support (IRVS) during initial 24 hours of hospitalization were categorised as IRVS+[30]. *P. aeruginosa*-CAP was defined as any patient with a confirmed diagnosis of CAP in whom *P. aeruginosa* was isolated in any respiratory fluid, including pleural effusion, sputum and/or bronchoalveolar lavage, and/or in the blood. Drug-resistant *P. aeruginosa* was defined when the isolated pathogen was resistant to ≥ 1 antibiotic and MDR *P. aeruginosa* was defined by resistance to ≥ 3 of the evaluated antibiotics. Antibiotic resistance to the following anti-pseudomonal antibiotics were evaluated: piperacillin/tazobactam, cefepime, ceftazidime, amikacin, gentamicin, tobramycin, levofloxacin, ciprofloxacin, imipenem, meropenem, doripenem, colistin and polymyxin B.

Prior *P. aeruginosa* infection/colonization was defined as confirmed infection/colonization within the last year before the hospitalization, documented by the patient or available patient records. Chronic obstructive pulmonary disease (COPD) was defined according to FEV1/FVC ratio < 0.7 and a compatible clinical history (including smoking history if relevant). Very severe COPD was defined as patients with COPD with evidence of very severe obstruction, determined by FEV1 $< 30\%$ prior to hospital admission (see online supplement for the complete study dictionary). Site investigators were given these definitions in the study protocol manual and study dictionary prior to starting data collection[26].

Statistical analysis

The prevalence of *P. aeruginosa* as microbiological aetiology of CAP (*i.e.*, *P. aeruginosa*-CAP) was calculated based on the counts of *P. aeruginosa* isolates divided by the study cohort (*i.e.*, CAP patients with microbiological test done), and is expressed as percentages. Chi-squared tests were used to compare categorical variables, which were expressed as counts and percentages. Continuous variables are presented as medians with interquartile ranges (IQR) and nonparametric Mann-Whitney U test was used to compare them. To assess the relationship between CAP due to *P. aeruginosa* and 67 demographic, clinical, epidemiological, and treatment variables, stepwise logistic regression model was executed. P-value < 0.05 was defined as statistically significant.

Tableau desktop, professional edition for Mac, was used to generate prevalence maps. All statistical analyses were performed with IBM SPSS, Statistics for Mac, version 22.0, Armonk, NY: IBM Corp.

RESULTS

A total of 3,193 patients were recruited during four study days from 222 hospitals in 54 countries (1,877 [58.8%] males, median [IQR] age: 68 [54-80] years). The demographics, risk factors, comorbidities, severity of illness, and chronic treatments are reported in Table 1. Among the 6 continents, most patients were recruited from Europe (1,941 [60.8%]), followed by North America (484 [15.2%]), Asia (405 [12.7%]), South America (203 [6.4%]), Africa (128 [4.0%]) and Oceania (32 [1.0%]). Microbiological cultures were obtained from blood (2,211 [69.2%]), sputum (1,630 [51.0%]), and bronchoalveolar lavage (311 [9.7%]). At least one pathogen was identified in 1,173 patients (36.7%), Figure e1. Tables 2 and e1 display the prevalence of *P. aeruginosa*-CAP and antibiotic-resistant *P. aeruginosa*-CAP per continents and countries.

Prevalence of *Pseudomonas aeruginosa*-CAP

P. aeruginosa-CAP was identified in 133 (4.2%) patients, representing 11.3 % (133/1,173) of all patients that had a positive culture for bacterial pathogens. The continental prevalence of *P. aeruginosa*-CAP was, 3.8% in Europe, 4.3% in North America, 5.2% in Asia, 4.9% in South America, 5.5% in Africa and 3.1% in Oceania, respectively (Figure 1). The prevalence of *P. aeruginosa*-CAP in each country, and a comparison between continents and countries is shown in Table 2 and e1. No statistically significant difference was found in the prevalence of *P. aeruginosa*-CAP among different continents. Croatia was the only country with statistically significant higher prevalence of *P. aeruginosa*-CAP (Table e1).

Prevalence of antibiotic-resistant *P. aeruginosa*-CAP

Antibiotic-resistant *P. aeruginosa*-CAP was identified in 64 (2.0%) patients, representing 5.4% (64/1,173) of all patients that had a positive culture. The continental prevalence of antibiotic-resistant *P. aeruginosa*-CAP was 1.6% in Europe, 2.5% in North America, 2.2% in Asia, 3.0% in South America, and 3.9%

in Africa, respectively (Figure 1). There were no patients with antibiotic-resistant *P. aeruginosa*-CAP identified in Oceania. No statistically significant difference was found in the prevalence of antibiotic-resistant *P. aeruginosa*-CAP among different continents (Table 2).

Prevalence of multi-drug resistant *P. aeruginosa*-CAP

MDR *P. aeruginosa* was identified in 33 (1.0%) patients, representing 2.8% (33/1,173) of all patients that had a positive culture. The continental prevalence of MDR *P. aeruginosa*-CAP was 0.9% in Europe, 1.2% in North America, 0.5% in Asia, 2% in South America, and 2.3% in Africa, respectively. There were no patients with MDR *P. aeruginosa* identified in Oceania. No statistically significant difference was found in the prevalence of MDR *P. aeruginosa*-CAP among different continents. No patients were infected with pan-drug resistant *P. aeruginosa* (*i.e.*, resistant to ≥ 3 groups of antibiotics and colistin) [31].

Risk factors

Patient demographics and risk factors were compared among *P. aeruginosa*-CAP and non-*P. aeruginosa* CAP (Table 1). The risk factors independently associated with *P. aeruginosa*-CAP in the multivariate analysis were prior pseudomonas infection/colonization (OR: 16.10 95% CI: 9.48, 27.35), prior tracheostomy (OR: 6.50, 95% CI: 2.61, 16.19), bronchiectasis (OR: 2.88, 95% CI: 1.65, 5.05), IRVS (OR: 2.33 95% CI: 1.44, 3.78) and very severe COPD (OR: 2.76 95% CI: 1.25, 6.06) (Table 3, Figure e2). Moreover, the risk factors associated with antibiotic-resistant *P. aeruginosa*-CAP were prior pseudomonas infection/colonization (OR: 17.29, 95% CI: 9.95, 33.42), tracheostomy (OR: 5.55, 95% CI: 1.73, 17.80) and IRVS (OR: 3.12, 95% CI: 1.63, 5.97). The risk factors found to be only statistically significant in the bivariate analysis were: COPD, coronary artery disease, inhaled corticosteroid use, indwelling catheter, and lower respiratory tract infection/ER visits/Hospitalisations/antibiotic treatments during the last 12 months (Table e3). Table 3 shows all the risk factors that had a statistically significant association with the different antibiotic resistance patterns (multivariate analyses are presented in Tables e2).

Figure 2 emphasizes the importance of the prevalence of *P. aeruginosa*-CAP, either one of the two main cluster of risk factors were tested among all the patients hospitalised with CAP or after stratifications based on the requirement of IRVS. Among all the patients with CAP, only 11% had risk factors (previously infected/colonization by pseudomonas and had chronic lung diseases [*i.e.*, tracheostomy, bronchiectasis and/or very severe COPD]). The lack of these two sets of risk factors (*i.e.*, previously infected/colonization by pseudomonas and tracheostomy, bronchiectasis and/or very severe COPD based on FEV1) confirms that only 2-6% of patients might still be affected, independent of the need of IRVS. The sensitivity, specificity, positive/negative predictive values and positive/negative likelihood ratios of these risk factors are presented in table e3.

DISCUSSION

This multinational point-prevalence study found a low prevalence of *P. aeruginosa* among hospitalised patients with CAP. Only 4.2%, 2.0% and 1.0% of hospitalised patients had CAP due to *P. aeruginosa*, antibiotic-resistant *P. aeruginosa*, or multidrug-resistant (MDR) *P. aeruginosa*, respectively. No patients were identified with pan-drug resistant *P. aeruginosa*. There was no statistically significant difference in prevalence rates between different continents. Croatia was the only country with statistically significant higher *P. aeruginosa*-CAP prevalence. Prior pseudomonas infection/colonization, tracheostomy, bronchiectasis, IRVS, and very severe COPD were independently associated with *P. aeruginosa*-CAP. Moreover, patients admitted with CAP with a past medical history of pseudomonas infection/colonization or chronic lung diseases (*i.e.*, tracheostomy, bronchiectasis and/or very severe COPD) had a higher risk of being infected with antibiotic-resistant *P. aeruginosa*.

Deciding empirical treatment for CAP patients has become challenging due to the emerging prevalence of drug-resistant bacteria, such as *P. aeruginosa*[6]. In a large retrospective study of culture positive patients in the United States, *Kollef et al.* reported a 19% prevalence of *P. aeruginosa* in hospitalised patients with CAP[15]. In a prospective cohort study in Europe, *Chalmers et al.* reported a 0.7% prevalence of *P. aeruginosa* among all patients enrolled with CAP and 2.2% among those with positive cultures[32]. Recently, *Jain et al.*

found *P. aeruginosa* in 0.4% of patients with CAP in a prospective cohort study in the United States and 1% among the patients with culture positive pneumonia[5]. We found the multinational point prevalence of *P. aeruginosa* as the causative pathogen of CAP was 4.2%, which corresponds to 11.3% of patients with positive culture pneumonia. Variations in the prevalence rates reported by different studies may be explained by differences in study design, especially the denominator used to calculate the prevalence rates[26]. However, these newly reported prevalence rates of *P. aeruginosa*–CAP are lower than prior reports[13-15], suggesting that only a small subgroup of patients may require empiric anti-pseudomonal antibiotic coverage.

The IDSA/ATS CAP guidelines recommend an antipseudomonal β -lactam antibiotic *plus* a fluoroquinolone or aminoglycoside in patients with risk factors for *P. aeruginosa*-CAP[13]. Dual antibiotic coverage has been recommended for HCAP, HAP, or VAP, where multidrug resistant pseudomonas is thought to be an important problem[25]. Our results challenge this approach, by showing that the worldwide prevalence of MDR *P. aeruginosa* in patients with CAP is very low (1% or 3% among culture positive pneumonia patients). Our results are consistent with the evidence from Spain by *Cilloniz et al.* who reported a prevalence of multidrug-resistant *P. aeruginosa* of 1.1% in a prospective cohort study of culture positive CAP patients[33]. Therefore, the recommended use of double antipseudomonal empirical coverage overestimates the actual rates of multidrug-resistant *P. aeruginosa* compared to what it is found in infections acquired in hospital settings, where the resistance rates seems to be higher than in patients coming from the community. However, it is suggested that patients critically ill with septic shock due to pneumonia should receive empiric double antipseudomonal coverage[25].

Several researchers have hypothesised that studies assessing the prevalence of pathogens responsible for CAP are difficult to generalize because these studies are conducted in different environments (*i.e.*, single hospital, regional, country or continent) with specific differences in healthcare delivery, including antibiotic availability and policies for antimicrobial use[19, 21, 23, 34]. In our study, we found that the prevalence of *P. aeruginosa*-CAP was not significantly different between participating centres representing different continents. In contrast, Croatia was the only country that had statistically significant higher *P. aeruginosa*-CAP prevalence. This study is novel by enrolling patients in a large number of centres representing more than 50 countries from

all over the world to identify the prevalence of *P. aeruginosa* in CAP patients.

In general, many hospitalised patients receive initial empiric anti-pseudomonal coverage while waiting 48-72 hours for specific pathogen identification and antibiotic susceptibilities[1, 3]. This practice has increased the use of broad-spectrum antibiotic agents and promoted antibiotic overuse with the risk of inducing antimicrobial resistance[11, 26]. Additionally, the delay between initial diagnosis and availability of antibiotic susceptibilities could negatively affect outcomes in patients with CAP due to inappropriate antibiotic coverage[13]. Therefore, initiation of empiric anti-pseudomonal coverage should be based on the likelihood that a pathogen circulates in the affected community and the presence of specific risk factors for *P. aeruginosa*-CAP[6, 13, 25]. In this regard, the risk factors listed in the IDSA/ATS pneumonia guidelines for *P. aeruginosa*-CAP are ICU admission, structural lung diseases, such as bronchiectasis, or COPD with multiple exacerbations[13]. Several risk factors have been reported for *P. aeruginosa*-CAP during the last few decades[6], but these previously reported risk factors (*e.g.*, heart failure, tube feeding[35], etc.) were statistically significant in the bivariate analysis of our study, but not in the multivariable analysis. In contrast, we found that prior pseudomonas infection/colonization, prior tracheostomy, bronchiectasis, IRVS, and very severe COPD (FEV1 \leq 30%) were independently associated with *P. aeruginosa*-CAP. These findings support the recommendation to consider these risk factors for empiric anti-pseudomonal antibiotics in patients with severe pulmonary diseases; but not in all patients with structural lung diseases. More importantly, patients with previous *P. aeruginosa* infection/colonization are at highest risk for *P. aeruginosa*-CAP and could benefit from empiric anti-pseudomonal antibiotic coverage, regardless of disease severity. Using these specific risk factors differs from the approach recommended by the IDSA/ATS guidelines and may help prevent overuse of anti-pseudomonal antibiotics in patients with CAP. More importantly antimicrobial stewardship programs that attempt to minimize the use of anti-pseudomonal coverage among patients without the specific pseudomonas risk factors may help prevent adverse events and overuse of unnecessary antimicrobial therapies.

This point prevalence study has some limitations. First, we were not able to determine clinical outcomes due to the study design. However, to determine prevalence rates and identify risk factors, point prevalence studies are ideal because they generate large sample sizes and gather generalizable data. Second,

microbiological samples were not collected to do centralised antibiotic susceptibility testing due to the experimental design and feasibility. Nevertheless, laboratories at study sites were encouraged to follow the CLSI or EUCAST guidelines to determine antibiotic resistance[28, 29]. Third, microbiological diagnosis of patients with CAP could be confounded by other pathogens colonizing the respiratory tract; however, in our study we only reported pathogens with representative growth according to current clinical guidelines for CAP. Fourth, infections other than pneumonia are possible, but less likely to present in patients with clinical signs and symptoms and radiological confirmation of CAP. Fifth, quality assessments were not performed because all data gathered were de-identifiable; however, all local investigators were instructed on how to enrol patients and how to use the data collection platform as described in the study protocol, data dictionary and the instructional video. Sixth, cystic fibrosis (CF) is a frequent cause of chronic *P. aeruginosa* colonization, although the majority of patients with CF might be included in the bronchiectasis group, CF was not directly recorded in our study. Finally, the empiric selection of antibiotics and diagnostic approach was performed according to the health care provider and it was not according to pre-specified criteria.

In conclusion, this multinational, point prevalence study found that the burden of *P. aeruginosa*, antibiotic-resistant *P. aeruginosa*, and multidrug-resistant *P. aeruginosa* as the etiologic pathogen of CAP is low (less than 5%). We identified five risk factors associated with *P. aeruginosa*-CAP: prior pseudomonas infection/colonization, tracheostomy, bronchiectasis, IRVS, and very severe COPD. These risk factors could serve to guide empiric anti-pseudomonal antibiotic treatment. Absence of these specific risk factors suggests that the empiric antibiotic treatment recommended for CAP patients will cover the most likely prevalent bacterial pathogens. Empiric anti-pseudomonal coverage should be reserved for a small subgroup of well-defined patients with a past medical history of pseudomonas infection/colonization and severe lung diseases (*i.e.*, prior tracheostomy, bronchiectasis and/or very severe COPD), regardless of disease severity. Importantly, not all patients with chronic pulmonary diseases would require empiric antipseudomonal coverage for CAP.

FUNDING

This project was unfunded. However, Nilam Soni's time is partially funded by the Department of Veterans Affairs, Quality Enhancement Research Initiative (QUERI) Partnered Evaluation Initiative Grant (HX002263-01A1). The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs, nor the United States Government.

ACKNOWLEDGMENTS

We would like to thank the European Respiratory Society, the World Federation of Societies of Intensive and Critical Care Medicine, the American College of Chest Physicians, the Asociación Latinoamericana de Tórax (ALAT), and the Sociedad Argentina de Infectología (SAI) for their support of this project.

GLIMP INVESTIGATORS

We would like to thank the following study contributors for their valuable collaboration:

Argentina: Patricia Karina Aruj, Department of Internal Medicine, University Hospital Alfredo Lanari, Buenos Aires, Argentina; Silvia Attorri, Hospital Luis Lago maggiore, Mendoza, Argentina; Enrique Barimboim, Hospital Central de Mendoza, Argentina; Juan Pablo Caeiro and María I. Garzón, Hospital Privado Universitario, Córdoba, Argentina; Victor Hugo Cambursano, V.H. Dr. Cazaux A. Servicio de Neumología, Hospital Rawson, Córdoba, Argentina; Adrian Ceccato, Hospital Nacional Prof. Alejandro Posadas, Argentina; Julio Chertcoff, Florencia Lascar and Fernando Di Tulio, Critical Care Unit and Respiratory Medicine, Buenos Aires British Hospital, Buenos Aires, Argentina; Ariel Cordon Díaz, Hospital General Alvear, Ciudad, Mendoza, Argentina; Lautaro de Vedia, Respiratory Intensive Care Unit, Hospital Muñiz, Buenos Aires, Argentina; Maria Cristina Ganaha, Infectious Diseases Ward, Hospital Interzonal General de Agudos "Vicente Lopez y Planes" from General Rodriguez, Buenos Aires, Argentina; Sandra Lambert, Hospital El Cruce - Alta Complejidad en Red, Argentina; Gustavo Lopardo, Hospital Bernardo Houssay, Vicente López, Argentina; Carlos M. Luna, Pulmonary Medicine Division, Department of Medicine, Hospital de Clínicas, Universidad de Buenos Aires, Argentina; Alessio Gerardo Malberti, Hospital

Nuestra Señora del Carmen, Argentina; Nora Morcillo and Silvina Tartara, Hospital Zonal Especializado de Agudos y Crónicos Dr. Antonio A. Cetrangolo, Argentina; Claudia Pensotti, Infectious Diseases and Infection Control Department, Buenos Aires, Clinica Privada Monte Grande, Argentina; Betiana Pereyra, Hospital San Roque, Córdoba, Argentina; Pablo Gustavo Scapellato, Infectious Diseases Department, Hospital D.F. Santojanni, Argentina; Juan Pablo Stagnaro, HZGA Mi Pueblo, Florencio Varela, Argentina. **Australia:** Sonali Shah, Department of General medicine, Austin hospital, Heidelberg, Australia. **Austria:** Felix Lötsch and Florian Thalhammer, Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Austria. **Belgium:** Kurt Anseeuw, ZNA Campus Stuivenberg, Antwerp, Belgium; Camille A. Francois, Anesthesia and critical care department, Erasme university hospital, Brussels, Belgium; Eva Van Braeckel, Department of Respiratory Medicine, Ghent University Hospital, Belgium; Jean Louis Vincent, Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. **Benin:** Marcel Zannou Djimon, Jules Bashi and Roger Dodo, Centre Hospitalier Universitaire HKM of Cotonou, Benin. **Brazil:** Simone Aranha Nouér, Federal University of Rio de Janeiro, Brazil. **Bulgaria:** Peter Chipev and Milena Encheva, Clinic of Pulmonary Diseases, Military Medical Academy, Sofia, Bulgaria; Darina Miteva, UMHAT "St. Marina", Varna, Bulgaria; Diana Petkova, University Hospital Varna, Bulgaria. **Cameroon:** Adamou Dodo Balkissou, Yaounde Jamot Hospital, Yaounde, Cameroon; Eric Walter Pefura Yone, Département de Médecine Interne, University of Yaounde, Yaoundé, Cameroon; Bertrand Hugo Mbatchou Ngahane, Douala General Hospital, Douala, Cameroon. **China:** Ning Shen, Respiratory Medicine, Peking University Third Hospital, Beijing, China; Jin-fu Xu, Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University, China. **Colombia:** Carlos Andres Bustamante Rico and Ricardo Buitrago, Clinica Shaio, Bogota, Colombia; Fernando Jose Pereira Paternina, Las Americas Clinic, Medellin, Colombia. **Congo:** Jean-Marie Kayembe Ntumba, Cliniques Universitaires de Kinshasa, DR Congo. **Croatia:** Vesna Vladic Carevic, Interne Medicine, Dubrovnik, Croatia; Marko Jakopovic, Medical School, University of Zagreb, Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia; Mateja Jankovic, University Hospital Center Zagreb, Department for Respiratory Diseases, Zagreb, Croatia; Zinka Matkovic, University Hospital Dubrava, Zagreb, Croatia; Ivan Mitrecic,

Karlovac general hospital, Karlovac, Croatia. **Denmark:** Marie-Laure Bouchy Jacobsson, Emergency Department in North Zealand's Hospital – Hillerød, Denmark; Anette Bro Christensen, Department of Anaesthesiology, Viborg Region Hospital, Denmark; Uffe Christian Heitmann Bødtger, Department of Pulmonology, Naestved Hospital, Denmark; Christian Niels Meyer, Department of Internal Medicine, Roskilde Hospital, Copenhagen University Hospital, Roskilde, Denmark; Andreas Vestergaard Jensen, Gertrud Baunbæk-knudsen, Pelle Trier Petersen and Stine Andersen, Department of Lung- and Infectious Diseases, Nordsjællands Hospital-Hillerød, Denmark. **Egypt:** Ibrahim El-Said Abd El-Wahhab, Thoracic Medicine, Faculty of Medicine - Mansoura University, Egypt; Nesreen Elsayed Morsy, Pulmonary, Critical Care and Sleep Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Hanaa Shafiek, Chest diseases department, Faculty of Medicine, Alexandria University, Egypt; Eman Sobh, Chest Diseases Department, Al-Azhar University, Cairo, Egypt. **Ethiopia:** Kedir Abdella Abdulsemed, Department of Medical Laboratory Science and Pathology, College of Health sciences, Mycobacteriology Research Centre, Institute of Biotechnology Research, Jimma University, Jimma, Ethiopia. **France:** Fabrice Bertrand, Critical care Unit, Robert Ballanger Hospital, Aulnay sous Bois, France; Christian Brun-Buisson, Univ Hospital Henri Mondor, 94000 Créteil, France; Etienne de Montmollin, Intensive care unit, Hôpital Delafontaine, Centre hospitalier de Saint-Denis, Saint-Denis, France; Muriel Fartoukh, Unité de réanimation médico-chirurgicale, Pôle Thorax Voies aériennes, Hôpital Tenon, Groupe Hospitalier Est Parisien, France; Jonathan Messika, Publique-Hôpital de Paris, Service de Réanimation Médico-chirurgicale, Hôpital Louis Mourier, Colombes, France, and Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; Pierre Tattevin, Infectious Diseases & ICU, Pontchaillou University Hospital, Rennes, France; Abdo Khoury, Department of Emergency Medicine & Critical Care, University of Franche - Comté, Medical Center, France. **Gambia:** Bernard Ebruke, Medical Research Council Unit, Gambia. **Germany:** Michael Dreher, Department of Cardiology, Pneumology, Vascular Medicine and Intensive Care Medicine, University Hospital Aachen, Aachen, Germany; Martin Kolditz, Division of Pulmonology, Medical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Matthias Meisinger, Klinikum Niederlausitz GmbH, Klinik für Innere Medizin und Intensivmedizin, Senftenberg, Germany; Mathias

W. Pletz and Stefan Hagel, Center for Infectious Diseases and Infection Control, Jena University Hospital, Germany; Jan Rupp, Department of Molecular and Infectious Diseases, University of Lübeck, Lübeck, Germany; Tom Schaberg, Zentrum für Pneumologie, Agaplesion Diakonieklinikum Rotenburg, Germany; Marc Spielmanns, Internal Medicine Department, Pulmonary rehabilitation and Department of Health, School of Medicine, University Witten-Herdecke, St.Remigius-Hospital, Leverkusen, Germany; Petra Creutz and Norton Suttorp, Department of Infectious Disease and Respiratory Medicine, Charité - University Medicine, Berlin, Germany. **Ghana:** Beatrice Siaw-Lartey, Komfo-Anokye Teaching Hospital, Kumasi, Ghana. **Greece:** Katerina Dimakou, 5th Respiratory Medicine Dpt, "SOTIRIA" Chest Hospital, Athens 11527, Greece; Dimosthenis Papapetrou, Medical Group of Athens (Paleo Faliro Clinic), Athens, Greece; Evdoxia Tsigou and Dimitrios Ampazis, Agioi Anargiroi Hospital, Kifissia, Athens, Greece; Evangelos Kaimakamis, Intensive Care Unit, "G. Papanikolaou" General Hospital of Thessaloniki, Greece. **India:** Mohit Bhatia, S.S. Hospital IMS BHU Varanasi, India; Raja Dhar, Fortis Hospitals, Kolkata, India; George D'Souza, Department of Pulmonary Medicine, St. John's Medical College Hospital, Bangalore, India, 560034; Rajiv Garg, Department of Respiratory Medicine, King George's Medical University UP, Lucknow, India; Parvaiz A Koul, Department of Internal & Pulmonary Medicine, SheriKashmir Institute of Medical Sciences, Srinagar, India; PA Mahesh and BS Jayaraj, Department of Pulmonary Medicine, JSS Medical College, JSS University, Mysore, India; Kiran Vishnu Narayan, Pulmonary Medicine, Government Medical College Kozhikode, Kerala, India; Hirennappa B Udnur and Shashi Bhaskara Krishnamurthy, Columbia Asia Hospital, Hebbal, Bengaluru, Karnataka, India; Surya Kant, Department of Respiratory Medicine, King George's Medical University, Chowk, Lucknow 226003, Uttar Pradesh, India; Rajesh Swarnakar, Getwell Hospital & Research Institute, Dhantoli, Nagpur, India; Sneha Limaye and Sundeep Salvi, on behalf of the Respiratory Research Network of India (RRNI) from the Chest Research Foundation in Pune, India. **Iran:** Keihan Golshani, Isfahan University of Medical Sciences; Iran. **Ireland:** Vera M Keatings, Letterkenny General Hospital, Co. Donegal, Ireland; Ignacio Martin-Loeches, Multidisciplinary Intensive Care Research Organization (MICRO), St James's University Hospital, Trinity Centre for Health Sciences Dublin, Ireland. **Israel:** Yasmin Maor, Infectious Disease Unit, Affiliated to Tel Aviv University, Wolfson Medical Center, Holon, Israel; Jacob Strahilevitz, Department of Clinical

Microbiology & Infectious Diseases, Hadassah-Hebrew University, Jerusalem, Israel. **Italy:** Salvatore Battaglia, University of Palermo, Pneumologia DiBiMIS, Palermo, Italy; Maria Carrabba, Internal Medicine Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122, Milano, Italy; Piero Ceriana, Pulmonary rehabilitation, IRCCS Fondazione Maugeri, 27100, Pavia, Italy; Marco Confalonieri, Department of Pulmunology, University Hospital, Trieste, Italy; Antonella d'Arminio Monforte, Department of Health Sciences, Clinic of Infectious Disease, San Paolo Hospital, University of Milan, Italy; Bruno Del Prato, Interventional Pneumology, Hospital Antonio Cardarelli, Naples, Italy; Marino De Rosa, UOC Pneumologia P.O. San Filippo Neri ASL RM E Roma, Italy; Riccardo Fantini, Respiratory Diseases clinic, Policlinico di Modena, 41124 Modena, Italy; Giuseppe Fiorentino, UOC Fisiopatologia e Riabilitazione Respiratoria AO Ospedali dei Colli PO Monaldi, Italy; Maria Antonia Gammino, Pulmonary Medicine Unit, San Martino Hospital, ASL 5 Oristano, Sardegna, Italy; Francesco Menzella, Department of Cardiac-Thoracic-Vascular and Intensive Care Medicine, Pneumology Unit, IRCCS- Arcispedale Santa Maria Nuova, Reggio Emilia, Italy; Giuseppe Milani, Azienda Ospedaliera Sant Anna di Como, Presidio Ospedale S. Anna Nuovo, Unità Operativa di Pneumologia, Como, Italy; Stefano Nava, Alma Mater University of Bologna, DIMES, Respiratory and Critical Care Unit Sant'Orsola Malpighi Hospital, Italy; Gerardo Palmiero, Respiratory Unit, Versilia Hospital, Azienda USL 12 Viareggio, Lido di Camaiore, Lucca, Italy; Roberta Petrino and Barbra Gabrielli, Emergency Medicine Unit, S. Andrea Hospital, Vercelli, Italy; Paolo Rossi, Internal Medicine Department, Azienda Ospedaliero-Universitaria S. Maria della Misericordia, Udine, Italy; Claudio Sorino, Pulmonology Unit, A.O. Sant'Anna di Como, Italy; Gundi Steinhilber, Spedali Civili Brescia, U.O. Pneumologia e Fisiopatologia Respiratoria, Brescia, Italy; Alessandro Zanforlin, ULSS 18 Rovigo, Ospedale San Luca, 45027 Trecenta (RO), Italy; Fabio Franzetti, Manuela Carugati, Manuela Morosi and Elisa Monge, Department of Biomedical and Clinical Sciences, Division of Infectious Diseases, Luigi Sacco Hospital, Università degli Studi di Milano, Milan, Italy; Mauro Carone, Fondazione Salvatore Maugeri, IRCCS, Cassano Murge, Italy; Vincenzo Patella, Allergology and Clinical Immunology Unit, Department of Medical Sciences, Battipaglia Hospital, Battipaglia, Salerno, Italy; Simone Scarlata, Geriatrics, Unit of Respiratory Pathophysiology and Thoracic Endoscopy, Campus Bio Medico University and Teaching Hospital, Rome, Italy; Andrea Comel, UO Pneumologia,

Ospedale Pederzoli, Peschiera del Garda, Italy. **Japan:** Kiyoyasu Kurahashi, Yokohama City University Medical Center, Japan. **Lebanon:** Zeina Aoun Bacha, Medicine school, St Joseph University, Beyrouth, Lebanon. **Mexico:** Daniel Barajas Ugalde, National Institute of Respiratory Diseases, Mexico; Omar Ceballos Zuñiga, Hospital General de Mexicali, Mexicali, Baja California, Mexico; José F Villegas, Hospital Universitario Monterrey, n. 1. México CP 64030. **Montenegro:** Milic Medenica, Hospital for Lung Diseases - Brezovik, Niksic, Montenegro. **Netherlands:**

E.M.W. van de Garde, Dept. Clinical Pharmacy, St. Antonius Hospital, Utrecht/Nieuwegein, The Netherlands.

Nepal: Deebya Raj Mihsra, Internal Medicine, BP Koirala Institute of Health Sciences, Nepal; Poojan Shrestha, Oxford University Clinical Research Unit, Patan Hospital, Nepal; **New Zealand:** Elliott Ridgeon, Medical

Research Institute of New Zealand; **Nigeria:** Babatunde Ishola Awokola, Department of Family Medicine & Primary Care, Lily Hospitals Limited, Warri, Nigeria; Ogonna N.O. Nwankwo, University of

Calabar Teaching Hospital, Calabar, Nigeria; Adefuye Bolanle Olufunlola, Olabisi Onabanjo University teaching hospital, Sagamu, Ogun State, Nigeria; Segalolu Olumide, Department of Medicine (Pulmonary Unit),

University College Hospital, Ibadan, Nigeria; Kingsley N. Ukwaja, Department of Medicine, Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria; **Pakistan:** Muhammad Irfan, Section of Pulmonary and Critical Care

Medicine, Department of Medicine, Aga Khan University, Karachi-74800, Pakistan; **Poland:** Lukasz Minarowski, Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Poland;

Skoczyński Szymon, Department of Pneumology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Institute of Occupational Medicine and Environmental Health, Sosnowiec, Poland; **Portugal:**

Felipe Froes, Hospital Pulido Valente - CHLN, Lisboa, Portugal; Pedro Leuschner, Centro Hospitalar do Porto, Porto, Portugal; Mariana Meireles, Cláudia Ferrão, Pedro Leuschner and João Neves, Serviço de Medicina,

Centro Hospitalar do Porto, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal; Sofia B Ravara, Faculty of Health Sciences, University of Beira Interior; Cova da Beira Hospital Center, 6200-251 Covilhã, Portugal;

Republic of Moldova: Victoria Brocovschii, Department of Pneumology & Allergology, State University of Medicine and Pharmacy "Nicolae Testemitanu" Republic of Moldova; Chesov Ion, Clinic of Anesthesia and

Intensive Care "Valeriu Ghireg", Institute of Emergency Medicine, State University of Medicine and Pharmacy

"Nicolae Testemitanu", Chisinau, Republic of Moldova; Doina Rusu, SMFU "N.Testemitanu", Chisinau, Republic of Moldova; Cristina Toma, Department of Pneumology & Allergology, State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Republic of Moldova; **Romania:** Daniela Chirita, Hospital Sfântul Stefan, Bucharest, Romania; Carmen Mihaela Dorobat, Universitatea de Medicină și Farmacie "Gr. T. Popa" Iași și Facultatea de Medicină Stomatologică, Spitalul Clinic de Boli Infecțioase "Sfânta Parascheva" Iași și str. Octav Botez, nr. 2, 700116, Iași, Romania; **Russia:** Alexei Birkun, Department of Anesthesiology, Critical Care and Emergency Medicine, Medical Academy named after S. I. Georgievsky, Russian Federation; Anna Kaluzhenina, Volgograd State Medical University, Russia. **Saudi Arabia:** Abdullah Almotairi, King Fahad medical City (KFMC), Riyadh, KSA; Zakeya Abdulbaqi Ali Bukhary, College of Medicine, Taibah University, Medina, KSA; Jameela Edathodu, Al Faisal University, King Faisal Specialist Hospital, Riyadh, KSA; Amal Fathy, Pulmonary and respiratory critical care Medicine, Mansoura University Egypt, Affiliate at Taibah University, KSA; Abdullah Mushira Abdulaziz Enani and Nazik Eltayeb Mohamed, Infectious Diseases Section, Medical Specialties Department, King Fahad Medical City, Riyadh, KSA; Jawed Ulhadi Memon, Pulmonology Division, Department of Internal Medicine, King Fahad Hospital, Hofuf, Al Ahasa, 31982, KSA; Abdelhaleem Bella, Dammam University-Saudi Arabia and King Fahad Hospital, KSA. **Serbia:** Nada Bogdanović, Pulmonary department of KHC Dr.Dragiša Mišović, Belgrade, Serbia; Branislava Milenkovic, Clinic for Pulmonary Diseases, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; Dragica Pesut, University of Belgrade School of Medicine, Teaching Hospital of Pulmonology, Clinical Centre of Serbia, Belgrade, Serbia. **Spain:** Luis Borderias, Respiratory and Sleep Unit, Hospital San Jorge, Huesca, Spain; Noel Manuel Bordon Garcia, Barcelona Policlínic and Moises Broggi Hospital at sant Joan Despí, Spain; Hugo Cabello Alarcón, Sant Hospital Seu de Urgell, Catalonia, Spain; Catia Cilloniz and Antoni Torres, Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Spain; Vicens Diaz-Brito and Xavier Casas, Infectious diseases Unit and Pneumology Service, Parc Sanitari Sant Joan de Deu, Sant Boi, Barcelona, Spain; Alicia Encabo González, Hospital Complex of Pontevedra, Spain; Maria Luisa Fernández-Almira, Medicina

Interna, Hospital Universitario Central de Asturias, Spain; Miguel Gallego, Department of Respiratory Medicine, Hospital de Sabadell, Institut Universitari Parc Taulí-UAB, Sabadell, Spain. CIBER de Enfermedades Respiratorias, CIBERES, Bunyola, Spain; Inmaculada Gaspar-García, Department of Respiratory Medicine, Hospital Costa del Sol, Marbella, Málaga, Spain; Juan González del Castillo, Emergency Department, Hospital Universitario Clínico San Carlos, Madrid, Spain; Patricia Javaloyes Victoria, Hospital General Universitario de Alicante, Alicante, Spain; Elena Laserna Martínez, Hospital Mollet, Barcelona, Spain; Rosa Malo de Molina, University Hospital Puerta de Hierro Majadahonda, Madrid; Pedro J Marcos, Servicio de Neumología, Complejo Hospitalario Universitario de A Coruña (CHUAC), INIBIC, Sergas, Universidade de A Coruña (UDC), Spain; Rosario Menéndez, Pneumology Service, University and Polytechnic Hospital La Fe, Valencia, Spain; Ana Pando-Sandoval, Hospital Universitario Central de Asturias. Area de Gestion Clinica de Pulmon. Servicio de Neumologia, Oviedo, Spain; Cristina Prat Aymerich, Alicia Lacoma de la Torre and Ignasi García-Olivé, Microbiology Department and Pneumology Department, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Badalona, Spain. Universitat Autònoma de Barcelona. CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain; Jordi Rello and Silvia Moyano, Critical Care Department, Hospital Vall d'Hebron, Barcelona, Spain; Francisco Sanz, Servicio de Neumología, Consorci Hospital General Universitari de Valencia, Valencia, Spain; Oriol Sibila and Ana Rodrigo-Troyano, Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; Jordi Solé-Violán, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain; Ane Uranga, Pulmology Department, Hospital of Galdakao-Usansolo, Spain; Job FM van Boven, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Ester Vendrell Torra and Jordi Almirall Pujol, Intensive Care Medicine, Hospital de Mataró, Spain. **South Africa:** Charles Feldman, Division of Pulmonology, Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. **South Korea:** Ho Kee Yum, Inje Univ. Seoul Paik Hospital, South Korea. **Togo:** Arnauld Attannon Fiogbe, Pulmonology and Infectious Diseases Service/University hospital of Sylvanus Olympio, Lomé, Togo. **Tunisia:** Ferdaous Yanguï, Department of Pneumology, Hospital of Internal Forces Security (I.F.S), Marsa, Tunis, Tunisia. **Turkey:** Semra

Bilaceroglu, Izmir Dr. Suat Seren Training and Research Hospital for Thoracic Medicine and Surgery, Izmir, Turkey; Levent Dalar, Pulmonary Medicine, Istanbul Bilim University, Istanbul, Turkey; Ufuk Yilmaz, Suat Seren Chest Disease and Surgery Training and Research Hospital, İzmir, Turkey. **Ukraine:** Artemii Bogomolov, Vinnitsa National Pirogov Memorial Medical University, Vinnitsa regional antituberculosis hospital, Vinnitsa, Ukraine. **United Arab Emirates:** Naheed Elahi, Dubai Hospital, U.A.E. **United Kingdom:** Devesh J Dhasmana, Victoria Hospital, Kirkcaldy, NHS Fife, UK; Andrew Feneley, Rhiannon Ions, Julie Skeemer and Gerrit Woltmann, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK; Carole Hancock, Royal Respiratory Research Team, Royal Liverpool University Hospital, Liverpool, UK; Adam T Hill, Royal Infirmary and University of Edinburgh, UK; Banu Rudran, The Royal London Hospital, Barts Health Trust, London, UK; Silvia Ruiz-Buitrago and Marion Campbell, Hairmyres Hospital, Eaglesham Road, East Kilbride, G75 8RG, UK; Paul Whitaker, Department of Respiratory Medicine, St James's Hospital, Leeds, LS9 7TF, UK; Alexander Youzguin, Southport and Ormskirk Hospitals NHS Trust, UK; Anika Singanayagam, Imperial College Healthcare NHS Trust, London, UK. **United States of America:** Karen S Allen, University of Oklahoma Health Sciences Center, USA; Veronica Brito, Texas A&M Health Science Center, Division of Pulmonary, Critical Care and Sleep Medicine Baylor Scott & White Health, USA; Jessica Dietz, Fargo VA Health Care System, Fargo, North Dakota, USA; Claire E. Dysart and Susan M. Kellie, Clement J. Zablocki VA Medical Center, 5000 W. National Ave Milwaukee, WI 53295, USA, Division of Infectious Diseases, University of New Mexico School of Medicine, Raymond G. Murphy VA Medical Center, 1501 San Pedro SE Albuquerque, NM87108, USA; Ricardo A Franco-Sadud and Garnet Meier, Division of Hospital Medicine, Cook County Hospital, Chicago, USA; Mina Gaga, 7th Resp. Med. Dept and Asthma Center, Athens Chest Hospital, USA; Thomas L. Holland and Stephen P. Bergin, Department of Medicine, Duke University Medical Center and School of Medicine, Duke Clinical Research Institute, USA; Fayez Kheir, Department of Pulmonary Diseases, Critical Care & Environmental Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA; Mark Landmeier, Division of Pulmonary and Critical Care Medicine, Northwestern Memorial Hospital, Chicago, IL 60611, USA; Manuel Lois, John Peter Smith Hospital, Fort Worth, TX, 76104, USA; Girish B Nair,

Interstitial Lung Disease Program and Pulmonary Rehabilitation, SUNY Stony Brook Winthrop University Hospital, Mineola, NY 115501, USA; Hemali Patel, Department of Medicine, Division of General Internal Medicine, Hospital Medicine Group, University of Colorado, USA; Katherine Reyes, Henry Ford Hospital, Detroit, IL, USA; William Rodriguez-Cintron, Pulmonary/Critical Care Medicine VA Caribbean Healthcare System, USA; Shigeki Saito, Tulane University, New Orleans, USA; Nilam J. Soni, Julio Noda, Cecilia I. Hinojosa, Stephanie M. Levine, Luis F. Angel and Antonio Anzueto, Divisions of Hospital Medicine & Pulmonary/Critical Care Medicine, South Texas Veterans Health Care System, University of Texas Health Science Center San Antonio, San Antonio, TX, USA; K. Scott Whitlow, John Hipskind, Kunal Sukhija and Vicken Totten, Kaweah Delta Health Care District, Department of Emergency Medicine, Visalia, CA, USA; Richard G. Wunderink and Ray D. Shah, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. **Zambia:** Kondwelani John Mateyo, Department of Internal Medicine, University Teaching Hospital, Lusaka, Zambia. **Other investigators:** Lorena Noriega; Ezequiel Alvarado; Mohamed Aman; Lucía Labra.

REFERENCES

1. Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. *Lancet* 2015; 386(9998): 1097-1108.
2. World Health Organization. The top 10 causes of death. Geneva. 2013.
3. Wunderink RG, Waterer GW. Community-acquired pneumonia. *N Engl J Med* 2014; 370(19): 1863.
4. Musher DM, Thorner AR. Community-acquired pneumonia. *N Engl J Med* 2014; 371(17): 1619-1628.
5. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, McCullers JA, Pavia AT, Edwards KM, Finelli L, Team CES. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *N Engl J Med* 2015; 373(5): 415-427.
6. Sibila O, Rodrigo-Troyano A, Shindo Y, Aliberti S, Restrepo MI. Multidrug-resistant pathogens in patients with pneumonia coming from the community. *Curr Opin Pulm Med* 2016; 22(3): 219-226.

7. Palacio F, Reyes LF, Levine DJ, Sanchez JF, Angel LF, Fernandez JF, Levine SM, Rello J, Abedi A, Restrepo MI. Understanding the Concept of Health Care-Associated Pneumonia in Lung Transplant Recipients. *Chest* 2015; 148(2): 516-522.
8. Polverino E, Torres A, Menendez R, Cilloniz C, Valles JM, Capelastegui A, Marcos MA, Alfageme I, Zalacain R, Almirall J, Molinos L, Bello S, Rodriguez F, Blanquer J, Dorado A, Llevat N, Rello J, investigators HS. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. *Thorax* 2013; 68(11): 1007-1014.
9. Sibila O, Restrepo MI, Anzueto A. What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents). *Infect Dis Clin North Am* 2013; 27(1): 133-147.
10. Wunderink RG, Yin Y. Antibiotic Resistance in Community-Acquired Pneumonia Pathogens. *Semin Respir Crit Care Med* 2016; 37(6): 829-838.
11. Chalmers JD, Reyes LF, Aliberti S, Restrepo MI. Empirical Coverage of Methicillin-Resistant *Staphylococcus aureus* in Community-Acquired Pneumonia: Those Who Do Not Remember the Past Are Doomed to Repeat It. *Clin Infect Dis* 2016; 63(8): 1145-1146.
12. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev* 2009; 22(4): 582-610.
13. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr., Musher DM, Niederman MS, Torres A, Whitney CG, Infectious Diseases Society of A, American Thoracic S. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007; 44 Suppl 2: S27-72.
14. Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. *Curr Opin Infect Dis* 2009; 22(3): 316-325.

15. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. *Chest* 2005; 128(6): 3854-3862.
16. Restrepo MI, Anzueto A. The role of gram-negative bacteria in healthcare-associated pneumonia. *Semin Respir Crit Care Med* 2009; 30(1): 61-66.
17. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. *Arch Intern Med* 2002; 162(16): 1849-1858.
18. Sibila O, Laserna E, Maselli DJ, Fernandez JF, Mortensen EM, Anzueto A, Waterer G, Restrepo MI. Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia. *Respirology* 2015; 20(4): 660-666.
19. Waterer GW. Healthcare-associated pneumonia: Can we salvage anything from the wreckage? *Respirology* 2016; 21(1): 8-9.
20. Torres A, Cilloniz C, Ferrer M, Gabarrus A, Polverino E, Villegas S, Marco F, Mensa J, Menendez R, Niederman M. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. *Eur Respir J* 2015; 45(5): 1353-1363.
21. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. *Lancet Infect Dis* 2010; 10(4): 279-287.
22. Lopez A, Amaro R, Polverino E. Does health care associated pneumonia really exist? *Eur J Intern Med* 2012; 23(5): 407-411.
23. Restrepo MI, Aliberti S. Healthcare-associated pneumonia: where do we go next? *Clin Infect Dis* 2014; 58(3): 340-341.
24. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. *Clin Infect Dis* 2014; 58(3): 330-339.
25. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratala J, El Solh AA, Ewig S, Fey PD, File TM, Jr., Restrepo MI, Roberts JA, Waterer GW,

Cruse P, Knight SL, Brozek JL. Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 2016; 63(5): 575-582.

26. Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI, investigators G. Global initiative for meticillin-resistant *Staphylococcus aureus* pneumonia (GLIMP): an international, observational cohort study. *Lancet Infect Dis* 2016; 16(12): 1364-1376.

27. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009; 42(2): 377-381.

28. Wayne PCaLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. , 2015.

29. Hsueh PR, Ko WC, Wu JJ, Lu JJ, Wang FD, Wu HY, Wu TL, Teng LJ. Consensus statement on the adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in clinical microbiology laboratories in Taiwan. *J Microbiol Immunol Infect* 2010; 43(5): 452-455.

30. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, Pierce RJ, Armstrong JG, Korman TM, Holmes P, Obrosky DS, Peyrani P, Johnson B, Hooy M, Australian Community-Acquired Pneumonia Study C, Grayson ML. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. *Clin Infect Dis* 2008; 47(3): 375-384.

31. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012; 18(3): 268-281.

32. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, Choudhury G, Hill AT. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. *Clin Infect Dis* 2011; 53(2): 107-113.
33. Cilloniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrus A, Mensa J, Torres A. Microbial aetiology of community-acquired pneumonia and its relation to severity. *Thorax* 2011; 66(4): 340-346.
34. Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, Pesci A, Blasi F, Torres A. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. *Thorax* 2013; 68(11): 997-999.
35. von Baum H, Welte T, Marre R, Suttorp N, Ewig S, group Cs. Community-acquired pneumonia through Enterobacteriaceae and *Pseudomonas aeruginosa*: Diagnosis, incidence and predictors. *Eur Respir J* 2010; 35(3): 598-605.

TABLES

Table 1. Characteristics of patients with *Pseudomonas aeruginosa* community-acquired pneumonia (CAP) vs non-*P. aeruginosa*-CAP.

Variables	CAP n=3,193 n (%)	<i>P. aeruginosa</i> CAP n= 133 n (%)	No- <i>P. aeruginosa</i> CAP n= 3,060 n (%)	P value
Demographic characteristics, n (%)				
Age, median (IQR) years	68 (54, 80)	64.36 (52.5,78.5)	65.01 (54, 80)	0.748
Male	1,877 (58.8)	79 (59.4)	1,798 (58.8)	0.883
Underweight	150/2,055 (7.3)	9/89 (10.1)	141/1,966 (7.2)	0.297
Obesity	510 (16)	17 (12.8)	493 (16.1)	0.305
Respiratory past medical history, n (%)				
Active lung cancer	92 (2.9)	5 (3.8)	87 (2.8)	0.536
Asthma	234 (7.3)	8 (6)	226 (7.4)	0.553
Bronchiectasis	168 (5.3)	31 (23.3)	137 (4.5)	<0.001
Chronic aspiration	218 (6.8)	15 (11.3)	203 (6.6)	0.038
COPD	834 (26.1)	57 (42.9)	777 (25.4)	<0.001
Very severe COPD (FEV ₁ ≤30%)	90 (2.8)	16 (12.0)	74 (2.4)	<0.001
Current/former smoker	1,114 (34.9)	46 (34.6)	1,068 (34.9)	0.940
Interstitial lung disease	91 (2.8)	6 (4.5)	85 (2.8)	0.240
Obstructive sleep apnoea	123 (3.9)	6 (4.5)	117 (3.8)	0.687
Oxygen therapy at home	208 (6.5)	26 (19.5)	182 (5.9)	<0.001
Lung transplantation	7 (0.2)	1 (0.8)	6 (0.2)	0.180
Tracheostomy	50 (1.6)	15 (11.3)	35 (1.1)	<0.001
Cardiovascular past medical history, n (%)				
Arrhythmia	455 (14.2)	20 (15)	435 (14.2)	0.791
Coronary artery disease	526 (16.5)	33 (24.8)	493 (16.1)	0.008
Heart failure	418 (13.1)	25 (18.8)	393 (12.8)	0.046
Hypertension	1,444 (45.2)	62 (46.6)	1,382 (45.2)	0.742
Stroke	250 (7.8)	13 (5.2)	237 (7.7)	0.394
Chronic medications, n (%)				
Inhaled corticosteroids use	544 (17)	48 (36.1)	496 (16.2)	<0.001

Proton pump inhibitor use	907 (28.4)	58 (6.4)	849 (27.7)	<0.001
Statins use	670 (21)	37 (27.8)	633 (20.7)	0.048
Steroids use	268 (8.4)	21 (15.8)	268 (8.4)	0.002
Chronic interventions, n (%)				
Enteric tube feeding	48 (1.5)	8 (6)	40 (1.3)	<0.001
Haemodialysis	51 (1.6)	4 (3)	47 (1.5)	0.185
Indwelling catheter	67 (2.1)	11 (8.3)	56 (1.8)	<0.001
Immunosuppressive conditions, n (%)				
Active solid tumour	245 (7.7)	11 (4.5)	234 (7.6)	0.791
AIDS	57 (1.8)	1 (0.8)	56 (1.8)	0.358
Aplastic anaemia	13 (0.4)	0 (0)	13 (0.4)	0.451
Asplenia	12 (0.4)	0 (0)	12 (0.4)	0.469
Biological drug use	35 (1.1)	3 (2.3)	32 (1)	0.190
Chemotherapy in the last 3 months	134 (4.2)	4 (3)	130 (4.2)	0.485
Haematological malignancy	150 (4.70)	3 (2.3)	147 (4.8)	0.174
HIV infection	107 (3.4)	3 (2.3)	104 (3.4)	0.473
Immunocompromised patients	623 (19.5)	28 (21.1)	595 (19.4)	0.647
Neutropenia	44 (1.4)	1 (0.8)	43 (1.4)	0.527
Other immunosuppressive condition	125 (3.9)	11 (8.3)	114 (3.7)	0.008
Other chronic medical conditions, n (%)				
Chronic renal failure	349 (10.9)	15 (11.3)	334 (10.9)	0.895
Dementia	333 (10.4)	14 (10.5)	319 (10.4)	0.970
Diabetes mellitus	681 (21.3)	28 (4.1)	653 (21.3)	0.937
Liver disease	129 (4)	4 (3)	125 (4.1)	0.537
Malnutrition	289 (9.1)	20 (15)	269 (8.8)	0.014
Mental illness	220 (0.726)	10 (7.5)	210 (6.9)	0.770
Prosthetic material	100 (3.1)	2 (1.5)	98 (3.2)	0.271
Recurrent skin infections	55 (1.7)	4 (3.0)	51 (1.7)	0.245
Other non-medical conditions, n (%)				
Bedridden	353 (11.1)	28 (21.1)	325 (92.1)	<0.001
Contact sport	5 (0.2)	0 (0)	5 (0.2)	0.641
Healthcare worker	44 (1.4)	4 (3)	40 (1.3)	0.100
Homeless	31 (1)	0 (0)	31 (1)	0.243
Injection of illicit drugs	37 (1.2)	1 (0.8)	36 (1.2)	0.654

Living in crowded conditions	671 (21)	24 (18)	647 (21.1)	0.391
Nursing home resident	258 (8.1)	18 (13.5)	240 (7.8)	0.018
Worker in livestock meat industry	29 (0.9)	0 (0)	29 (0.9)	0.259
Previous infections/colonization, n (%)				
Prior MRSA infection/colonization	81 (2.5)	10 (7.5)	71 (2.3)	<0.001
Prior ESBL-producing bacterial infection	54 (1.7)	5 (3.8)	49 (1.6)	0.059
Prior <i>Pseudomonas aeruginosa</i> infection/colonization	96 (3)	44 (33.1)	52 (1.7)	<0.001
Prior healthcare exposure, n (%)				
Antibiotic infusion at home during the last 12 months	140 (4.4)	12 (9)	128 (4.2)	0.008
Emergency room admission in the last 12 months	972 (30.4)	63 (47.4)	909 (29.7)	<0.001
Hospitalizations during the last 12 months	1026 (32.1)	70 (52.6)	956 (31.2)	<0.001
IV antibiotics during the last 12 months	812 (25.4)	64 (48.1)	748 (24.4)	<0.001
LRTI in the last 12 months	928 (29.1)	66 (49.6)	862 (28.5)	<0.001
Oral antibiotics during the last 12 months	1219 (38.2)	77 (57.9)	1142 (37.3)	<0.001
Pneumonia severity, n (%)				
Invasive respiratory or vasopressor support (IRVS)	404 (12.7)	34 (25.6)	370 (12.1)	<0.001
ICU admission	599 (18.8)	43 (32.3)	556 (18.2)	<0.001
Non-invasive mechanical ventilation	334 (10.5)	15 (11.3)	319 (10.4)	0.753
CAP; Community-acquired pneumonia, MRSA; Methicillin resistant <i>Staphylococcus aureus</i> , COPD; Chronic obstructive pulmonary disease, FEV1; Forced expiratory volume during the first second, CAD; Coronary artery disease, ESBL; extended-spectrum beta-lactamases, LRTI; lower respiratory tract infections				

Table 2. Prevalence of antibiotic-resistant *Pseudomonas aeruginosa*-Community-acquired pneumonia (CAP) and antibiotic-resistant *P. aeruginosa*-CAP in participating centres representing different continents.

	CAP patients n=3,193					
	Continent		Rest of the world		OR (95% CI)	p value
	%	n	%	n		
<i>Pseudomonas aeruginosa</i>-CAP						
Global	4.2	133/3193
Africa	5.5	7/128	4.1	126/3065	1.34 (0.61, 2.95)	0.57
Asia	5.2	21/405	4.0	112/2788	1.30 (0.81, 2.10)	0.27
Europe	3.8	73/1941	4.8	60/1252	0.77 (0.54, 1.10)	0.15
North America	4.3	21/484	4.1	112/2,709	1.0 (0.65, 1.69)	0.83
Oceania	3.1	1/32	4.2	132/3161	0.74 (0.10, 5.46)	0.76
South America	4.9	10/203	4.1	123/2990	1.20 (0.62, 2.33)	0.57
Antibiotic resistant <i>Pseudomonas aeruginosa</i>-CAP						
Global	2	64/3193
Africa	3.9	5/128	1.9	59/3065	2.071 (0.817, 5.252)	0.125
Asia	2.2	9/405	2	55/2788	1.129 (0.554, 2.303)	0.738
Europe	1.6	32/1941	2.6	32/1252	0.639 (0.389, 1.049)	0.076
North America	2.5	12/484	1.9	52/2709	0.770 (0.408, 1.453)	0.420
Oceania	0	0/32	2	64/3161	.	0.416
South America	3	6/203	1.9	58/2990	1.540 (0.656, 3.612)	0.321
Multi-drug resistant <i>Pseudomonas aeruginosa</i>-CAP (≥ 3 antibiotics groups)						
Global	1.0	33/3193
Africa	2.3	3/128	1	30/3065	2.428 (0.731, 8.063)	0.135
Asia	0.5	2/405	1.1	31/2788	0.441 (0.105, 1.851)	0.250
Europe	0.9	18/1941	1.2	15/1252	0.772 (0.388, 1.537)	0.460
North America	1.2	6/484	1	27/2709	1.247 (0.512, 3.036)	0.626
Oceania	0	0/32	1	33/3161	.	0.561
South America	2	4/203	1	29/2990	2.052 (0.714, 5.895)	0.173
Carbapenem resistant <i>Pseudomonas aeruginosa</i>-CAP						
Global	1.1	34/3193
Africa	1.6	2/128	1.0	32/3065	1.504 (0.357, 6.348)	0.576
Asia	0.7	3/405	1.1	31/2788	0.664 (0.202, 2.181)	0.496
Europe	0.9	18/1941	1.3	16/1252	0.723 (0.367, 1.423)	0.346
North America	1.7	8/484	1.0	26/2709	1.734 (0.781, 3.854)	0.171
Oceania	0	0/32	1.1	34/3161	.	0.555
South America	1.5	3/203	1.0	31/2990	1.432 (0.434, 4.724)	0.554
Colistin resistant <i>Pseudomonas aeruginosa</i>-CAP						
Global	0.4	12/3193
Africa	0	0/128	0.4	12/3065	.	0.478
Asia	0.7	3/405	0.3	9/2788	2.304 (0.621, 8.547)	0.199
Europe	0.4	7/1941	0.4	5/1252	0.903 (0.286, 2.850)	0.861
North America	0	0/484	0.4	12/2709	.	0.142
Oceania	3.1	1/32	0.3	11/3161	9.238 (1.157, 73.754)	0.011
South America	0.5	1/203	0.4	11/2990	1.341 (0.172, 10.436)	0.779

Table 3. Multivariate analysis of risk factors for *Pseudomonas aeruginosa*-Community-acquired pneumonia (CAP), antibiotic resistant (AR) *P. aeruginosa*-CAP, multidrug-resistant (MDR) *P. aeruginosa*-CAP, and specific antibiotic resistance patterns.


	Prior <i>P. aeruginosa</i>	IRVS	Tracheostomy	Bronchiectasis	COPD	Very severe COPD
<i>P. aeruginosa</i>-CAP, n=133	16.10 (9.48-27.35)	2.33 (1.44-3.78)	6.50 (2.61-16.19)	2.88 (1.65-5.05)	.	2.76 (1.25-6.06)
AR <i>P. aeruginosa</i>-CAP, n=64	17.29 (9.95-33.42)	3.12 (1.63-5.97)	5.55 (1.73-17.80)	.	.	.
Anti-pseudomonal cephalosporins, n=38	17.79 (7.32-43.22)	.	.	.	2.58 (1.07-6.19)	.
Piperacillin/ Tazobactam, n=30	9.72 (3.88-24.36)	4.14 (1.75-9.81)	.	3.33 (1.21-9.19)	.	.
Carbapenems, n=34	10.62 (4.26-26.45)	2.70 (1.14-6.34)	10.77 (3.09-37.52)	.	.	.
Aminoglycosides, n=31	17.32 (7.21-41.61)	3.02 (1.24-7.31)
Quinolones, n=50	17.35 (8.28-36.38)	2.84 (1.39-5.78)	4.35 (1.21-15.60)	.	.	.
MDR <i>P. aeruginosa</i>- CAP, n=33	12.34 (5.05-30.14)	3.42 (1.47-7.97)	.	.	2.69 (1.10-6.55)	.
IRVS, invasive respiratory or vasopressor support; MDR, multidrug resistant, COPD, chronic obstructive pulmonary disease.						

FIGURE LEGENDS


Figure 1. Prevalence of *Pseudomonas aeruginosa*-Community-acquired pneumonia (CAP) and antibiotic-resistant *P. aeruginosa*-CAP by continents (Panel A and Panel B).


Figure 2. Prevalence of *Pseudomonas aeruginosa*-Community-acquired pneumonia (CAP) according to the relevant risk factors that include prior *Pseudomonas aeruginosa* (pPa) infection/colonization, grouped variables of severe lung diseases (LDz³: tracheostomy, bronchiectasis and very severe COPD [*i.e.*, FEV1 <30%]) and stratified according to the need of invasive respiratory and/or vasopressor support (IRVS).

A



B





pPa: prior *Pseudomonas aeruginosa*; **LDz³:** lung diseases independently associated with *Pseudomonas aeruginosa*-CAP (tracheostomy, bronchiectasis and COPD with FEV1 <30% [i.e., severe COPD]); **IRVS:** Invasive respiratory and/or vasopressor support.

ONLINE SUPPLEMENT

SUPPLEMENTARY TABLES

Table e1. Prevalence of *Pseudomonas aeruginosa* at participating centers representing different countries.

Countries	<i>Pseudomonas aeruginosa</i> -CAP prevalence n=3,193					OR (95% CI)	p value
	Continent/Country		Rest of the world				
	%	n	%	n			
Argentina	4.0	7/175	4.2	126/3018	0.95 (0.44, 2.08)	0.91	
Bulgaria	0	0/37	4.2	133/3156	.	0.20	
Croatia	12.8	12/94	3.9	121/3099	3.60 (1.91, 6.77)	<0.001	
Denmark	1.2	1/86	4.2	132/3107	0.26 (0.03, 1.91)	0.15	
France	3.2	2/63	4.2	131/3130	0.75 (0.18, 3.10)	0.59	
Germany	5.2	7/134	4.1	126/3059	1.28 (0.58, 2.80)	0.53	
Greece	3.5	3/85	4.2	130/3108	0.83 (0.26, 2.68)	0.76	
India	3.3	5/150	4.2	128/3043	0.78 (0.31, 1.94)	0.60	
Ireland	3.1	1/32	4.2	132/3161	0.74 (0.10, 5.46)	0.76	
Italy	3.7	14/381	4.2	119/2812	0.86 (0.49, 1.51)	0.60	
Moldova	0	0/31	4.2	133/3162	.	0.24	
Montenegro	0	0/1	4.2	133/3192	.	0.83	
Netherlands	4.7	2/43	4.2	131/3150	1.12 (0.26, 4.69)	0.87	
Pakistan	7.5	8/107	4.1	125/3086	1.91 (0.91, 4.02)	0.08	
Portugal	1	1/101	4.3	132/3092	0.22 (0.03, 1.62)	0.10	
Saudi Arabia	7.1	3/42	4.1	130/3151	1.78 (0.54, 5.86)	0.33	
Serbia	0	0/41	4.2	133/3152	.	0.17	
Spain	3.2	19/585	4.4	114/2608	0.73 (0.44, 1.20)	0.21	
United Kingdom	3.6	5/140	4.2	128/2053	0.84 (0.34, 2.10)	0.71	
United States	4.5	20/442	4.1	113/2751	1.10 (0.68, 1.80)	0.68	

TABLE e2. Bivariate analyses of risk factors for *Pseudomonas aeruginosa*-CAP, drug-resistance *P. aeruginosa*-CAP and multidrug resistance *P. aeruginosa*-CAP.

Bivariate <i>P. aeruginosa</i>-CAP		
Variable	Odds ratio (95% CI)	p-value
Underweight	1.46 (0.71, 2.96)	0.30
Obesity	0.76 (0.45, 1.28)	0.31
Either current or former smoker	0.99 (0.68, 1.42)	0.94
Alcoholism	0.79 (0.39, 1.56)	0.49
COPD	2.20 (1.55, 3.14)	<0.01
COPD with FEV1<30%	5.52 (3.12, 9.77)	<0.01
Oxygen therapy at home	3.84 (2.44, 6.05)	<0.01
Asthma	0.80 (0.39, 1.66)	0.55
Non-cystic fibrosis bronchiectasis	6.48 (4.18, 10.04)	<0.01
Interstitial Lung Disease	1.65 (0.71, 3.86)	0.24
Lung transplant	3.85 (0.46, 32.26)	0.21
OSAS	1.19 (0.51, 2.75)	0.69
Chronic aspiration	1.79 (1.03, 3.12)	0.04
Arrhythmia	1.07 (0.66, 1.74)	0.79
CAD	1.72 (1.15, 2.58)	<0.01
Heart failure	1.57 (1.00, 2.46)	0.05
Essential arterial hypertension	1.06 (0.75, 1.50)	0.74
Stroke	1.29 (0.72, 2.32)	0.39
HIV infection	0.66 (0.20, 2.09)	0.48
AIDS	0.41 (0.06, 2.96)	0.37
Active solid tumor	1.09 (0.58, 2.05)	0.79
Active lung cancer	1.33 (0.53, 3.34)	0.54
Hematological malignancy	0.46 (0.14, 1.45)	0.18
Chemotherapy in the last 3 months	0.70 (0.25, 1.92)	0.49
Neutropenia	0.53 (0.07, 3.89)	0.53
Biological drug use	2.18 (0.66, 7.22)	0.20
Other immunosuppressive condition	2.33 (1.22, 4.44)	0.01
Liver disease	0.73 (0.26, 2.00)	0.54
Cirrhosis	1.55 (0.55, 4.33)	0.40
Mental illness	1.10 (0.57, 2.13)	0.77
Dementia	1.01 (0.57, 1.78)	0.97
Diabetes mellitus	0.98 (0.64, 1.50)	0.94
Chronic renal failure	1.04 (0.60, 1.80)	0.90
Hemodialysis	1.99 (0.70, 5.60)	0.19
Prior mycobacterial diseases	4.254(2.30, 7.87)	<0.01
Recurrent skin infections	1.83 (0.65, 5.14)	0.25
Prior MRSA infection	3.42 (1.72, 6.80)	<0.01
Prior ESBL-producing bacterial infection	2.40 (0.94, 6.13)	0.07
Prior <i>Pseudomonas aeruginosa</i> infection/colonization	28.60 (18.18, 45.01)	<0.01
Inhaled corticosteroids use	2.92 (2.02, 4.21)	<0.01
Statins use	1.48 (1.00, 2.18)	0.05
Steroids use	2.13 (1.32, 3.46)	<0.01
Proton pump inhibitor use	2.01 (1.42, 2.86)	<0.01
ICU admission, n (%)	2.15 (1.47, 3.13)	<0.01
Invasive mechanical ventilation, n (%)	2.36 (1.53, 3.64)	<0.01

Non-invasive mechanical ventilation, n (%)	1.09 (0.63, 1.89)	0.75
Treatment with inotropes, n (%)	3.69 (1.41, 9.64)	<0.01
Treatment with vasopressors, n (%)	2.21 (1.33, 3.67)	<0.01
Malnutrition	1.84 (1.12, 3.00)	0.01
Bedridden	2.24 (1.46, 3.46)	<0.01
Living in crowded conditions	0.82 (0.52, 1.29)	0.39
Healthcare worker	2.34 (0.82, 6.64)	0.11
Nursing home resident	1.84 (1.10, 3.07)	0.02
Enteric tube feeding	4.83 (2.21, 10.54)	<0.01
Tracheostomy	10.99 (5.84, 20.67)	<0.01
Prosthetic material	0.46 (0.11, 1.89)	0.28
Indwelling catheter	4.84 (2.42, 9.46)	<0.01
Injection of illicit drugs	0.64 (0.09, 4.67)	0.66
Lower respiratory tract infections during the last 12 months	2.51 (1.77, 3.56)	<0.01
Emergency room admission during the last 12 months	2.13 (1.50, 3.02)	<0.01
Hospitalization during the last 12 months	2.44 (1.72, 3.66)	<0.01
Antibiotic infusion at home during the last 12 months	2.27 (1.22, 4.22)	<0.01
IV antibiotics during the last 12 months	2.87 (2.02, 4.07)	<0.01
Oral antibiotics during the last 12 months	3.48 (2.32, 5.22)	<0.01
Bivariate drug resistance <i>Pseudomonas aeruginosa</i>-CAP		
Underweight	1.35 (0.474, 3.82)	0.58
Obesity	0.86 (0.42, 1.75)	0.67
COPD	2.72 (1.66, 4.47)	<0.01
COPD with FEV1<30%	3.75 (1.57, 8.93)	<0.01
Oxygen therapy at home	5.10 (2.84, 9.15)	<0.01
Asthma	0.84 (0.30, 2.33)	0.74
Non-cystic fibrosis bronchiectasis	4.39 (2.30, 8.41)	<0.01
Interstitial Lung Disease	1.70 (0.52, 5.52)	0.38
OSAS	2.16 (0.85, 5.49)	0.10
Chronic aspiration	3.274 (1.72, 6.23)	<0.01
Arrhythmia	1.25 (0.65, 2.42)	0.50
CAD	2.18 (1.27, 3.76)	<0.01
Heart failure	1.89 (1.03, 3.45)	0.04
Essential arterial hypertension	1.68 (1.02, 2.77)	0.04
Stroke	2.23 (1.12, 4.43)	0.02
HIV infection	0.45 (0.06, 3.29)	0.45
Active solid tumor	1.25 (0.53, 2.93)	0.61
Active lung cancer	1.68 (0.52, 5.46)	0.39
Hematological malignancy	0.65 (0.16, 2.68)	0.55
Chemotherapy in the last 3 months	0.36 (0.05, 2.59)	0.31
Neutropenia	1.14 (0.15, 8.40)	0.90
Biological drug use	3.03 (0.71, 12.89)	0.13
Other immunosuppressive condition	2.12 (0.84, 5.39)	0.11
Liver disease	0.76 (0.18, 3.15)	0.71
Cirrhosis	2.47 (0.75, 8.10)	0.13
Mental illness	1.41 (0.60, 3.30)	0.43
Dementia	1.61 (0.81, 3.19)	0.17
Diabetes mellitus	0.94 (0.51, 1.74)	0.84
Chronic renal failure	1.52 (0.77, 3.02)	0.23
Hemodialysis	2.21 (0.48, 8.52)	0.33
Prior mycobacterial diseases	1.74 (0.53, 5.66)	0.36
Recurrent skin infections	2.91 (0.88, 9.58)	0.08

Prior MRSA infection	5.98 (2.75, 12.99)	<0.01
Prior ESBL-producing bacterial infection	5.33 (2.05, 13.85)	0.01
Prior <i>Pseudomonas aeruginosa</i> infection/colonization	32.36 (18.66, 56.12)	<0.01
Inhaled corticosteroids use	3.68 (2.22, 6.11)	<0.01
Statins use	1.37 (0.78, 2.40)	0.27
Steroids use	1.81 (0.89, 3.71)	0.10
Proton pump inhibitor use	2.58 (1.57, 4.23)	<0.01
Severe CAP	2.35 (1.43, 3.86)	<0.01
Malnutrition	2.63 (1.42, 4.90)	<0.01
Bedridden	2.53 (1.40, 4.56)	<0.01
Living in crowded conditions	0.78 (0.40, 1.49)	0.45
Healthcare worker	3.70 (1.12, 12.29)	0.03
Nursing home resident	2.42 (1.25, 4.70)	<0.01
Enteric tube feeding	3.37 (1.02, 11.14)	0.05
Tracheostomy	10.50 (4.71, 23.39)	<0.01
Prosthetic material	0.99 (0.24, 4.14)	0.99
Indwelling catheter	6.28 (2.75, 14.34)	<0.01
Lower respiratory tract infections during the last 12 months	2.83 (1.72, 4.66)	<0.01
Emergency room admission during the last 12 months	2.33 (1.42, 3.82)	<0.01
Hospitalization during the last 12 months	2.96 (1.79, 4.90)	<0.01
Antibiotic infusion at home during the last 12 months	4.83 (2.46, 9.46)	<0.01
IV antibiotics during the last 12 months	3.90 (2.36, 6.43)	<0.01
Oral antibiotics during the last 12 months	4.05 (2.31, 7.07)	<0.01
Bivariate Multidrug Resistance <i>Pseudomonas aeruginosa</i>-CAP		
Underweight	0.55 (0.07, 4.09)	0.56
Obesity	0.94 (0.36, 2.44)	0.90
Either current or former smoker	1.07 (0.52, 2.18)	0.86
Alcoholism	1.10 (0.33, 3.62)	0.88
COPD	3.45 (1.73, 6.87)	<0.01
COPD with FEV1<30%	2.25 (0.53, 9.56)	0.27
Oxygen therapy at home	3.96 (1.70, 9.24)	<0.01
Asthma	1.76 (0.61, 5.04)	0.29
Non-cystic fibrosis bronchiectasis	4.11 (1.67, 10.10)	<0.01
Interstitial Lung Disease	1.07 (0.14, 7.89)	0.95
OSAS	2.53 (0.76, 8.42)	0.13
Chronic aspiration	2.47 (0.94, 6.46)	0.06
Arrhythmia	1.63 (0.70, 3.78)	0.25
CAD	2.23 (1.05, 4.71)	0.04
Heart failure	1.48 (0.61, 3.61)	0.39
Essential arterial hypertension	1.46 (0.73, 2.91)	0.28
Stroke	1.18 (0.36, 3.89)	0.79
HIV infection	0.90 (0.12, 6.65)	0.92
Active solid tumor	1.21 (0.36, 3.98)	0.76
Hematological malignancy	0.63 (0.09, 4.65)	0.65
Biological drug use	6.11 (1.40, 26.60)	0.02
Other immunosuppressive condition	2.49 (0.75, 8.27)	0.14
Cirrhosis	1.53 (0.21, 11.42)	0.67
Mental illness	1.88 (0.65, 5.40)	0.24
Dementia	1.19 (0.41, 3.40)	0.75
Diabetes mellitus	0.82 (0.34, 1.99)	0.66
Chronic renal failure	1.12 (0.39, 3.22)	0.83

Recurrent skin infections	1.80 (0.24, 13.39)	0.57
Prior MRSA infection	3.95 (1.18, 13.22)	0.03
Prior ESBL-producing bacterial infection	3.86 (0.90, 16.54)	0.07
Prior <i>Pseudomonas aeruginosa</i> infection/colonization	24.10 (11.59, 50.08)	<0.01
Inhaled corticosteroids use	3.22 (1.59, 6.51)	<0.01
Statins use	1.21 (0.54, 2.69)	0.64
Steroids use	1.09 (0.33, 3.60)	0.88
Proton pump inhibitor use	3.06 (1.54, 6.11)	<0.01
Severe CAP	2.80 (1.41, 5.59)	<0.01
Malnutrition	1.81 (0.69, 4.72)	0.23
Bedridden	1.80 (0.74, 4.39)	0.20
Living in crowded conditions	0.37 (0.11, 1.23)	0.104
Healthcare worker	7.61 (2.23, 25.93)	<0.01
Nursing home resident	2.05 (0.78, 5.36)	0.14
Enteric tube feeding	4.37 (1.01, 18.79)	0.05
Tracheostomy	9.34 (3.15, 27.64)	<0.01
Prosthetic material	2.02 (0.48, 8.54)	0.34
Indwelling catheter	4.84 (1.44, 16.26)	<0.01
Lower respiratory tract infections during the last 12 months	3.36 (1.68, 6.73)	<0.01
Emergency room admission during the last 12 months	2.17 (1.09, 4.31)	0.03
Hospitalization during the last 12 months	2.56 (1.29, 5.10)	<0.01
Antibiotic infusion at home during the last 12 months	5.02 (2.04, 12.36)	<0.01
IV antibiotics during the last 12 months	3.58 (1.79, 7.13)	<0.01
Oral antibiotics during the last 12 months	5.18 (2.41, 11.15)	<0.01
CAD: Coronary artery disease; CAP: Community-acquired pneumonia; COPD: Chronic Obstructive pulmonary disease; OSAS: Obstructive sleep apnea syndrome; AIDS: Acquired Immune Deficiency Syndrome; HIV: Human immunodeficiency virus; FEV1: Forced expiratory volume in one second; MRSA: Methicillin-resistant staphylococcus aureus; ESBL: Extended-spectrum beta-lactamase		

Table e3. Positive and negative predictive value of the risk factors identified for *P. aeruginosa* in patients with CAP (*i.e.*, pPa: prior *P. aeruginosa* colonization or infection and LDz³: tracheostomy, bronchiectasis and very severe COPD); stratified by patients that required invasive mechanical ventilation or vasopressors (IVRS).

		Sensitivity, %	Specificity, %	Positive likelihood ratio	Negative likelihood ratio	Positive predictive value, %	Negative predictive value, %
CAP cohort (n=3,193)	pPa (+) and LDz ³ (+)	21.0 (14.5-28.9)	99.5 (99.2-99.7)	46.0 (24.8-85.3)	0.8 (0.7-0.9)	66.7 (51.9-78.8)	96.7 (96.4-96.9)
	pPa (+) and LDz ³ (-)	12.0 (7.0-18.8)	98.8 (98.3-99.1)	9.7 (5.5-16.9)	0.9 (0.8-0.9)	29.6 (19.4-42.4)	96.3 (96.0-96.5)
	pPa (-) and LDz ³ (+)	19.5 (13.2-27.3)	92.8 (91.8-93.7)	2.7 (1.9-3.9)	0.9 (0.8-0.9)	10.6 (7.6-14.6)	96.4 (96.1-96.6)
	pPa (-) and LDz ³ (-)	52.6 (43.8-61.3)	91.1 (90.0-92.1)	5.9 (4.9-7.2)	0.5 (0.4-0.6)	20.5 (17.4-23.9)	97.8 (97.4-98.1)
IRSV – cohort (n=2,789)	pPa (+) and LDz ³ (+)	25.2 (17.1-35.0)	99.5 (99.2-99.7)	26.6 (29.3-109.4)	0.7 (0.7-0.8)	67.6 (51.9-80.1)	97.3 (97.9-97.6)
	pPa (+) and LDz ³ (-)	13.1 (7.2-21.4)	98.9 (98.5-99.3)	12.2 (6.5-22.7)	0.9 (0.8-0.9)	30.9 (19.4-45.5)	96.9 (96.6-97.1)
	pPa (-) and LDz ³ (+)	19.2 (11.9-28.3)	93.0 (92.0-94.0)	2.8 (1.8-4.2)	0.9 (0.8-1.0)	9.2 (6.2-13.5)	96.9 (96.6-97.2)
	pPa (-) and LDz ³ (-)	57.6 (47.2-67.4)	91.5 (90.4-92.5)	6.8 (5.5-8.4)	0.5 (0.4-0.6)	20.0 (16.8-23.6)	98.3 (97.9-98.7)
IRSV + cohort (n=404)	pPa (+) and LDz ³ (+)	8.8 (1.9-23.7)	99.5 (98.1-99.9)	16.32 (2.8-94.3)	0.9 (0.8-1.0)	60.0 (20.6-89.6)	92.2 (91.4-92.9)
	pPa (+) and LDz ³ (-)	8.8 (1.9-23.7)	97.6 (95.4-98.9)	3.63 (1.0-12.8)	0.9 (0.8-1.0)	25.0 (8.6-54.0)	92.1 (91.3-92.9)
	pPa (-) and LDz ³ (+)	20.6 (8.7-37.9)	91.1 (87.7-93.8)	2.3 (1.1-4.8)	0.9 (0.7-1.0)	17.5 (9.2-30.7)	92.6 (91.3-93.7)
	pPa (-) and LDz ³ (-)	38.2 (22.2-56.4)	88.1 (84.4-91.2)	3.2 (1.9-5.3)	0.7 (0.5-0.9)	22.8 (15.1-33.0)	93.9 (92.2-95.3)

All values are presented with 95% Confidence of Interval. **pPa**: prior *Pseudomonas aeruginosa*; **LDz³**: lung diseases independently associated with *Pseudomonas aeruginosa*-CAP (tracheostomy, bronchiectasis and COPD with FEV1 <30% [*i.e.*, severe COPD]); **IRVS**: Invasive respiratory and/or vasopressor support.

SUPPLEMENTARY FIGURE LEGENDS

Figure e1. Flowchart of patients hospitalized with community-acquired pneumonia (CAP) enrolled in the study.

Figure e2. Multivariate analysis of the risk factors independently associated with *Pseudomonas aeruginosa*-Community-acquired pneumonia (CAP).

SUPPLEMENTARY FIGURES

Figure e1.





Figure e2.



SUPPLEMENTARY DOCUMENTS

1. Study manual.

GLIMP STUDY MANUAL AND DEFINITIONS

1. Male/female: checked box about the gender of the subject
2. Health care worker: health professional in health care services (e.g.: nurse, physicians, dentist, physiotherapist, etc.).
3. Livestock/meat industry worker: employee working with domestic animals, such as cattle, for home use or for profit, including production of meat and dairy products.
4. Nursing home resident: A patient living in a facility or institution that provides health care such as rehabilitation, restorative and skilled nursing care to patients in need of assistance with activities of daily living, especially for elderly people.
5. Bedridden/Bedbound: patient confined to a bed for at least a month prior to hospital admission, mainly because of a poor performance status.
6. Community and crowded living: a setting with close contacts such as prison, dormitories, shelter, barracks, etc.
7. Previous influenza virus vaccination: influenza vaccination during the prior and/or current influenza season.
8. Previous conjugate pneumococcal vaccination: prior pneumococcal vaccination with a conjugate vaccine (such as PCV7, PCV10 or PCV13).
9. Previous polysaccharide pneumococcal vaccination: prior pneumococcal vaccination with a 23-valent pneumococcal polysaccharide vaccine (PPSV23).

Section 2

2. Low respiratory tract infections: respiratory infections including pneumonia, acute exacerbation of COPD and acute exacerbation of bronchiectasis.

3. COPD Exacerbation: an event in the natural course of the COPD characterized by a worsening of the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management.
4. Emergency room visits: emergency room visits for any reason.
5. Hospitalizations: hospital admission for more than 24 hours for any reason.
6. Home antibiotic infusion therapy: intravenous antibiotic administration through a permanent or temporary catheter for any reason at home.
7. Intravenous antibiotic courses: intravenous antibiotic courses for any reason.
8. Oral antibiotic courses: antibiotic administered through the mouth for any reason.

Section 3

1. Aspiration: history of previous episodes of aspiration, with or without dysphagia.
2. Chronic renal failure: an estimated glomerular filtration rate $< 60 \text{ mL/min/1.73m}^2$ during at least six months before hospital admission.
3. Chronic arrhythmia: presence of any of the following arrhythmias: atrial flutter, atrial fibrillation, junctional supraventricular, paroxysmal supraventricular tachycardia, ventricular tachycardia during at least six months before hospital admission.
4. Aplastic anemia: deficiency of all types of blood cells or pancytopenia (anemia, leukopenia and thrombocytopenia) due to failure of the bone marrow.
5. HIV: human immunodeficiency virus infection, regardless of the number of CD4+ lymphocytes/mm³.
6. Asthma: prior clinical diagnosis of bronchial asthma during at least six months before hospital admission.

7. Chronic hemodialysis: need of hemodialysis during at least six months before hospital admission.
8. Mental illness: any psychiatric disorder including depression and excluding dementia during at least six months before hospital admission.
9. Asplenia: absence of the spleen (anatomical asplenia) or presence of a spleen that does not function (functional asplenia).
10. AIDS: either human immunodeficiency virus infection with < 200 CD4+ lymphocytes/mm³ or acquired immune deficiency syndrome (AIDS)-defining conditions.
11. Heart failure: A clinical diagnosis of left ventricular failure or congestive cardiac failure for at least six months before hospital admission.
12. Bronchiectasis: presence of abnormal dilatation of bronchi on computed tomography scan of the thorax.
13. Dementia: impairment of at least two brain functions, including memory, thinking, judgment, language and social abilities such as performing daily activities during at least six months before hospital admission.
14. Active solid tumor: any active solid tumor, excluding lung cancer and hematological malignancy before hospital admission.
15. Stroke: either ischemic and/or hemorrhagic stroke before hospital admission.
16. Homeless: people without a regular home before hospital admission.
17. Injectable drugs: any current use of injectable drugs (e.g. cocaine, heroin, etc.) before hospital admission.
18. Myocardial infarction: a past medical history consistent with acute myocardial infarction.

19. Interstitial lung diseases: any diffuse parenchymal lung disease before hospital admission (e.g. idiopathic pulmonary fibrosis [IPF], nonspecific interstitial pneumonia [NSIP], etc.).
20. Lung transplantation: having one or both lungs transplanted.
21. Alcoholism: chronic condition characterized by excessive use of alcohol on a regular basis.
22. Coronary artery disease: history of coronary artery disease, including angina (stable or unstable), before hospital admission.
23. Neutropenia: less than 500 neutrophils/dL on the complete blood count before hospital admission.
24. Obesity: body mass index (BMI) ≥ 30 . BMI calculation: $\text{weight (Kg)} / (\text{height (m)})^2$.
25. Hematological malignancy: any active hematological malignancy (including lymphoma, acute or chronic leukemia and multiple myeloma) before hospital admission.
26. Contact sport: currently participating in any sport requiring skin-to-skin contact before hospital admission (e.g. rugby, wrestling, soccer, basketball, etc.).
27. Chronic liver disease: any liver disease *excluding* cirrhosis during at least six months before hospital admission (e.g. chronic viral hepatitis, nonalcoholic hepatitis, etc.).
28. Chronic biological drugs: use of biological drugs, including anti-cancer therapies such as trastuzumab and therapies for autoimmune diseases such as anti-TNF α , during at least six months before hospital admission.
29. Recurrent skin infections: more than one skin infection during one year before hospital admission (e.g. skin abscess, folliculitis, chronic skin ulceration).

30. Chronic inhaled steroids: use of any kind of inhaled steroids, such as beclomethasone, budesonide, fluticasone, or mometasone, on a regular basis (at least 3 times a week) during at least six months before hospital admission.
31. Prosthetic material: any prior implantation of prosthetic material, including cardiac valves or orthopedic replacement, excluding dental implants.
32. Cirrhosis: Clinical diagnosis of features consistent with hepatic fibrosis and nodular regeneration during at least six months before hospital admission.
33. Chronic indwelling catheter: need to maintain an indwelling catheter (including bladder catheter and central venous catheter) during at least six months before hospital admission.
34. Diabetes Mellitus: diagnosis of diabetes mellitus, whether type I or Type II before hospital admission.
35. Chronic steroids: steroid treatment > 10 mg of prednisone/daily or equivalent during at least three months before hospital admission.
36. Prior mycobacteria disease: any past medical history of mycobacterial infection or colonization including *Mycobacterium tuberculosis* complex and non- tuberculous mycobacteria.
37. Malnutrition: chronic poor nutrition identified through laboratories (e.g. low levels of plasma protein), physical exam (e.g. low BMI) or medical history before hospital admission.
38. COPD: chronic obstructive pulmonary disease defined according to FEV₁/FVC ratio <0.7 and a compatible clinical history (including smoking history if relevant)
39. Hypertension: chronic systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or chronic need of any antihypertensive treatment to maintain systemic arterial pressure below these levels during at least six months before hospital admission.
40. Other immunosuppression: any immunosuppressive state including congenital/genetic

immunosuppression and immunosuppressive therapy due to hematological/solid organ transplantation other than lung (excluding hematological malignancies, asplenia, aplastic anemia, neutropenia, chronic biological drugs, chronic steroid treatment, HIV/AIDS and chemotherapy) during at least six months before hospital admission.

41. Chemotherapy in the prior 3 months: any chemotherapy in the previous 3 months before hospital admission.
42. Enteral tube feedings: chronic feeding through a tube directly into the gastrointestinal tract (including nasogastric tube and percutaneous endoscopic gastrostomy tube –PEG-) before hospital admission.
43. FEV1 <30%: Forced Expiratory Volume in the 1st second < 30% of predicted reference values calculated according to gender, age, height and weight.
44. Chronic use of proton pump inhibitors: any proton pump inhibitors use on a regular basis during at least six months before hospital admission.
45. Home oxygen therapy: chronic/long term need of oxygen supply to correct hypoxia due to cardiac and/or pulmonary diseases (even at a stable state of the disease) before hospital admission.
46. Chronic statin use: any statin uses on a regular basis during at least six months before hospital admission.

Section 4

Severity of the disease within 24 hours after hospital admission, including:

1. Admission to an Intensive Care Unit (ICU) or a High-dependency unit (HDU, also known as respiratory intensive care unit or semi-intensive care unit or progressive care unit) within the first 24 hours after hospital admission.
2. Non-invasive mechanical ventilation (NIV) during the first 24 hours of hospital admission.

3. Invasive mechanical ventilation during the first 24 hours after hospital admission.
4. Vasopressors use, including epinephrine, norepinephrine or dopamine, within the first 24 hours after hospital admission.
5. Inotropes use, including dobutamine, within the first 24 hours after hospital admission.

Section 5

Please indicate if during the past year the patient was infected or colonized with one of the following pathogens prior to hospital admission.

Mark if during the year prior of the current hospitalization the patient had documented infection due to Methicillin Resistant *Staphylococcus aureus* (MRSA); *Pseudomonas aeruginosa* or Extended Spectrum Beta-Lactamase producing Gram negative bacilli (ESBL).

Section 6

Please indicate all the diagnostic tests performed within 24 hours of hospital admission. This question refers to the tests ordered and actually performed during the first 24 hours of hospital admission. The answers are self-explanatory.

Section 7

Please indicate if a pathogen was identified (whether cultured or other test) as the possible responsible etiology for the patient admitted with pneumonia. In case the investigator selects the **box YES**, a series of boxes (as shown in the pdf case report form) will appear for the documentation **UP TO 2** microorganisms:

- 1 - Select the name of the pathogen
- 2 - Select the source of the pathogen (***select ALL that apply***) - Select antibiotic susceptibilities (a list of pre-specified antimicrobial resistance patterns will appear in the e-CRF. ***Please check ALL that apply***).

Section 8

Please indicate *ALL the antibiotics or antimicrobial agents* administered during the first 24 hours of admission to the hospital.

- *Select ALL THE NAMES THAT APPLY*